{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:04:51Z","timestamp":1788267891959,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science and Technology Innovation Team of Shanxi Province","award":["202204051002030"],"award-info":[{"award-number":["202204051002030"]}]},{"name":"Research project supported by Shanxi Scholarship Council of China","award":["2023-100"],"award-info":[{"award-number":["2023-100"]}]},{"name":"Fundamental Research Program of Shanxi Province","award":["202303021211197"],"award-info":[{"award-number":["202303021211197"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The immunosuppressive tumor microenvironment (TME) is a cardinal driver of immune escape and resistance to immunotherapy in renal cell carcinoma (RCC). The N6-methyladenosine (m\n                      <jats:sup>6<\/jats:sup>\n                      A), the most prevalent RNA modification, critically governs tumor aggressiveness and TME reprogramming. We aimed to exploit whether and how tumor-intrinsic m\n                      <jats:sup>6<\/jats:sup>\n                      A modification driven by ZC3H13 (zinc finger CCCH-type containing 13) can dictate the immune landscape of RCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Loss- and gain-of-function studies were performed in vitro and in allograft tumor model. Tumor-infiltrating immune cells were profiled with flow cytometry and immunostaining. The pivotal cytokine mediated by ZC3H13 depletion was identified through an integrated analysis of RNA-seq and PCR array. The molecular target of ZC3H13 was elucidated through integrated m\n                      <jats:sup>6<\/jats:sup>\n                      A sequencing and RNA sequencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Low ZC3H13 expression was an independent predictor of poor prognosis in RCC. Functionally, ZC3H13 silencing enhanced the malignant behaviors of RCC cells and drove an immunosuppressive microenvironment characterized by aberrant recruitment of myeloid-derived suppressor cells (MDSCs). Mechanistically, ZC3H13 promoted m\n                      <jats:sup>6<\/jats:sup>\n                      A methylation on UNC5CL (UNC-5 Family C-Terminal Like) mRNA, facilitating YTHDC1-mediated stabilization of UNC5CL transcripts, which subsequently suppressed the NF-\u03baB-CSF2 signaling axis, ultimately inhibiting MDSCs accumulation. Furthermore, therapeutic targeting CSF2 in combination with anti-PD1 exerts stronger antitumor effects in RCC by synergistically reversing the MDSCs mediated immunosuppressive microenvironment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We identified that ZC3H13 loss unleashes the NF-\u03baB-CSF2 signaling cascade via m\n                      <jats:sup>6<\/jats:sup>\n                      A-dependent silencing of UNC5CL, converting the RCC milieu into an MDSCs-dominated immunosuppressive niche. Targeting CSF2 combined with anti-PD1 may represent a novel therapeutic strategy to achieve better efficacy in RCC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03742-2","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:01:38Z","timestamp":1779278498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epitranscriptomic silencing of the ZC3H13\/m6A axis orchestrates immunosuppressive microenvironment remodeling in renal cell carcinoma via CSF2-mediated MDSCs recruitment"],"prefix":"10.1186","volume":"45","author":[{"given":"Jinxiu","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"10","key":"3742_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41581-025-00983-w","volume":"21","author":"FH Burgers","year":"2025","unstructured":"Burgers FH, et al. Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors. Nat Rev Nephrol. 2025;21(10):687\u2013701.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3742_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"3742_CR3","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1038\/s41598-025-88682-1","volume":"15","author":"Z Qiao","year":"2025","unstructured":"Qiao Z, et al. A comparative analysis of global and Chinese trends in the burden of kidney cancer from 1990 to 2021. Sci Rep. 2025;15(1):4558.","journal-title":"Sci Rep"},{"issue":"1","key":"3742_CR4","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3742_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1158\/0008-5472.CAN-23-2521","volume":"84","author":"G Shu","year":"2024","unstructured":"Shu G, et al. PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma. Cancer Res. 2024;84(10):1659\u201379.","journal-title":"Cancer Res"},{"issue":"4","key":"3742_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199\u2013214.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3742_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"key":"3742_CR8","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. Integrated transcriptomic analysis identifies MZT2A as a prognostic and immune-related biomarker in KIRC. Int J Surg. 2025;111(11):8748\u201350.","DOI":"10.1097\/JS9.0000000000003062"},{"issue":"1","key":"3742_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.","journal-title":"Mol Cancer"},{"issue":"6","key":"3742_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6(6):924\u201337.","journal-title":"Nat Cancer"},{"issue":"11","key":"3742_CR11","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.immuni.2025.10.013","volume":"58","author":"K Bi","year":"2025","unstructured":"Bi K, et al. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity. 2025;58(11):2814\u20132829.e9.","journal-title":"Immunity"},{"issue":"4","key":"3742_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","volume":"23","author":"A van Weverwijk","year":"2023","unstructured":"van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer. 2023;23(4):193\u2013215.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3742_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","volume":"23","author":"J Wei","year":"2024","unstructured":"Wei J, et al. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 2024;23(1):279.","journal-title":"Mol Cancer"},{"issue":"4","key":"3742_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen H, et al. METTL3 Inhibits Antitumor Immunity by Targeting m(6)A-BHLHE41-CXCL1\/CXCR2 Axis to Promote Colorectal Cancer. Gastroenterology. 2022;163(4):891\u2013907.","journal-title":"Gastroenterology"},{"issue":"4","key":"3742_CR15","doi-asserted-by":"publisher","first-page":"e2403936","DOI":"10.1002\/advs.202403936","volume":"12","author":"MB Uddin","year":"2024","unstructured":"Uddin MB, Wang Z, Yang C. Epitranscriptomic RNA m(6)A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities. Adv Sci (Weinh). 2024;12(4):e2403936.","journal-title":"Adv Sci (Weinh)"},{"key":"3742_CR16","doi-asserted-by":"crossref","unstructured":"Monteagudo-Garc\u00eda \u00d3 et al. ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. Cancer Res. 2026;86(3):622\u201341.","DOI":"10.1158\/0008-5472.CAN-24-3975"},{"issue":"1","key":"3742_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00018-025-05596-x","volume":"82","author":"Q Sheng","year":"2025","unstructured":"Sheng Q, et al. The inhibition of ZC3H13 attenuates G2\/M arrest and apoptosis by alleviating NABP1 m6A modification in cisplatin-induced acute kidney injury. Cell Mol Life Sci. 2025;82(1):86.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"3742_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10565-024-09980-4","volume":"41","author":"L Huang","year":"2025","unstructured":"Huang L, et al. Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer. Cell Biol Toxicol. 2025;41(1):52.","journal-title":"Cell Biol Toxicol"},{"key":"3742_CR19","doi-asserted-by":"publisher","first-page":"578963","DOI":"10.3389\/fonc.2020.578963","volume":"10","author":"PJ Gong","year":"2020","unstructured":"Gong PJ, et al. Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer. Front Oncol. 2020;10:578963.","journal-title":"Front Oncol"},{"issue":"1","key":"3742_CR20","doi-asserted-by":"publisher","first-page":"e1547","DOI":"10.1002\/mgg3.1547","volume":"9","author":"Q Wang","year":"2021","unstructured":"Wang Q, et al. Clinicopathological and immunological characterization of RNA m(6) A methylation regulators in ovarian cancer. Mol Genet Genomic Med. 2021;9(1):e1547.","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"3742_CR21","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1038\/s41598-025-88671-4","volume":"15","author":"L Gao","year":"2025","unstructured":"Gao L, et al. Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma. Sci Rep. 2025;15(1):4412.","journal-title":"Sci Rep"},{"issue":"17","key":"3742_CR22","doi-asserted-by":"publisher","first-page":"17819","DOI":"10.1074\/jbc.M310737200","volume":"279","author":"J Zhang","year":"2004","unstructured":"Zhang J, et al. Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB. J Biol Chem. 2004;279(17):17819\u201325.","journal-title":"J Biol Chem"},{"issue":"11","key":"3742_CR23","doi-asserted-by":"publisher","first-page":"e2412123","DOI":"10.1002\/advs.202412123","volume":"12","author":"Q Yao","year":"2025","unstructured":"Yao Q, et al. METTL3 Potentiates M2 Macrophage-Driven MMT to Aggravate Renal Allograft Fibrosis via the TGF-\u03b21\/Smad3 Pathway. Adv Sci (Weinh). 2025;12(11):e2412123.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"3742_CR24","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2018.02.015","volume":"69","author":"J Wen","year":"2018","unstructured":"Wen J, et al. Zc3h13 Regulates Nuclear RNA m(6)A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Mol Cell. 2018;69(6):1028\u20131038.e6.","journal-title":"Mol Cell"},{"issue":"1","key":"3742_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s13577-024-01155-x","volume":"38","author":"B Liu","year":"2024","unstructured":"Liu B, et al. ZC3H13 promotes autophagy in bladder cancer through m6A methylation modification of PJA2 and ubiquitination of KSR1. Hum Cell. 2024;38(1):23.","journal-title":"Hum Cell"},{"key":"3742_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2022.01.013","volume":"530","author":"C Huang","year":"2022","unstructured":"Huang C, et al. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Cancer Lett. 2022;530:16\u201328.","journal-title":"Cancer Lett"},{"issue":"8","key":"3742_CR27","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jfma.2022.12.019","volume":"122","author":"R Xie","year":"2023","unstructured":"Xie R, et al. Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation. J Formos Med Assoc. 2023;122(8):738\u201346.","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"3742_CR28","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.18632\/aging.203939","volume":"14","author":"S Wu","year":"2022","unstructured":"Wu S, et al. Downregulation of ZC3H13 by miR-362-3p\/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma. Aging. 2022;14(5):2304\u201319.","journal-title":"Aging"},{"issue":"6","key":"3742_CR29","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-23-0430","volume":"30","author":"X Guo","year":"2024","unstructured":"Guo X, et al. Hypoxia-Induced Neuronal Activity in Glioma Patients Polarizes Microglia by Potentiating RNA m6A Demethylation. Clin Cancer Res. 2024;30(6):1160\u201374.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3742_CR30","doi-asserted-by":"publisher","first-page":"2392400","DOI":"10.1080\/15592294.2024.2392400","volume":"19","author":"H Zhuang","year":"2024","unstructured":"Zhuang H, et al. Expression patterns and clinical value of key m6A RNA modification regulators in smoking patients with coronary artery disease. Epigenetics. 2024;19(1):2392400.","journal-title":"Epigenetics"},{"key":"3742_CR31","doi-asserted-by":"publisher","first-page":"102801","DOI":"10.1016\/j.ctrv.2024.102801","volume":"129","author":"P Rioja","year":"2024","unstructured":"Rioja P, Rey-Cardenas M, De Velasco G. Targeting HIF-2\u03b1 and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma. Cancer Treat Rev. 2024;129:102801.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3742_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-024-02984-2","volume":"43","author":"C Montemagno","year":"2024","unstructured":"Montemagno C, et al. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001. J Exp Clin Cancer Res. 2024;43(1):86.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3742_CR33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jhep.2023.06.021","volume":"79","author":"L Wang","year":"2023","unstructured":"Wang L, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol. 2023;79(5):1185\u2013200.","journal-title":"J Hepatol"},{"issue":"7980","key":"3742_CR34","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","volume":"621","author":"C Wang","year":"2023","unstructured":"Wang C, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621(7980):830\u20139.","journal-title":"Nature"},{"issue":"2","key":"3742_CR35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","volume":"27","author":"DH Aggen","year":"2021","unstructured":"Aggen DH, et al. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clin Cancer Res. 2021;27(2):608\u201321.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3742_CR36","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun R, et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol Ther. 2023;31(11):3193\u2013209.","journal-title":"Mol Ther"},{"issue":"7","key":"3742_CR37","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1038\/emm.2016.64","volume":"48","author":"IS Hong","year":"2016","unstructured":"Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med. 2016;48(7):e242.","journal-title":"Exp Mol Med"},{"issue":"10","key":"3742_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41419-023-06163-7","volume":"14","author":"R Ji","year":"2023","unstructured":"Ji R, et al. IGF2BP2-meidated m(6)A modification of CSF2 reprograms MSC to promote gastric cancer progression. Cell Death Dis. 2023;14(10):693.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3742_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00018-024-05290-4","volume":"81","author":"GY Lian","year":"2024","unstructured":"Lian GY, et al. Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF production. Cell Mol Life Sci. 2024;81(1):262.","journal-title":"Cell Mol Life Sci"},{"key":"3742_CR40","doi-asserted-by":"publisher","first-page":"901277","DOI":"10.3389\/fimmu.2022.901277","volume":"13","author":"A Kumar","year":"2022","unstructured":"Kumar A, et al. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front Immunol. 2022;13:901277.","journal-title":"Front Immunol"},{"key":"3742_CR41","doi-asserted-by":"crossref","unstructured":"Zhang C, et al. Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis. J Clin Invest. 2024;134(8):e175703.","DOI":"10.1172\/JCI175703"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03742-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:03:40Z","timestamp":1781168620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03742-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3742"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03742-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8888264\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments complied with the regulations and guidelines of the ARRIVE Guidelines 2.0. (PLoS Bio 8(6), e1000412,2010). The protocols were approved by the Animal Research Ethics Committee at the Shanxi Medical University (2023SJL68). For the animal model employed in this research, the ethics committee has stipulated that the maximal allowable tumour diameter must not exceed 2\u00a0cm. We hereby confirm that the maximal tumour size permitted by our ethics committee was rigorously observed throughout the study. Tumour growth was closely monitored, and the health status of all experimental animals was regularly assessed. At no point during the course of the experiments did the tumour size in any animal exceed the predefined maximal limit of as mandated by our institutional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}